Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328469 | 0.89 | HSP90AA1 (0.35) | MAPTPNPDGAT1PDE2A | |
| SCHEMBL29661419 | 0.89 | HSP90AA1 (0.35) | MAPTPNPDGAT1PDE2A | |
| SCHEMBL21481639 | 0.86 | NT5E (0.38) | MAPTPNPDGAT1PDE2A | |
| SCHEMBL21303003 | 0.85 | MAPT (0.32) | MAPTPNPDGAT1PDE2A | |
| SCHEMBL26720567 | 0.82 | HSP90AA1 (0.36) | MAPTPNPDGAT1 | |
| SCHEMBL25048792 | 0.79 | DGAT1 (0.34) | MAPTDGAT1 | |
| SCHEMBL26720557 | 0.79 | DGAT1 (0.37) | PNPDGAT1KLKB1 | |
| SCHEMBL20262422 | 0.78 | DGAT1 (0.33) | MAPTDGAT1 | |
| SCHEMBL26102605 | 0.77 | BCDIN3D (0.42) | MAPTPDE2A | |
| SCHEMBL31497497 | 0.76 | DGAT1 (0.37) | MAPTDGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | MAPT 1165/4885PNP 3423/4885DGAT1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.